You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT JAMA
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 285 No. 17, May 2, 2001 TABLE OF CONTENTS
  JAMA
  •  Online Features
  Letters
 This Article
 •Full text
 •PDF
 •Correction
 •Correction
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citing articles on Web of Science (1)
 •Contact me when this article is cited
 Related Content
 •Related article
 •Similar articles in JAMA
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Outcomes of a Trial of HIV-1 Immunogen in Patients With HIV Infection

Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

To the Editor: Dr Kahn and colleagues1 claimed that after a disagreement between them and the sponsor, they published the incomplete, although generally negative, results of a trial of an immunologic modifier (Remune; The Immune Response Corp [IRC], Carlsbad, Calif) for human immunodeficiency virus (HIV) "to fulfill our responsibility to inform patients of the outcome of this study, and to contribute to their understanding of HIV-1 Immunogen if it was to be studied in another clinical trial." I find that the article is inconclusive for several reasons.

First, while the primary end point of the study was time to HIV progression, the authors only presented HIV progression rate. They did not include true temporal variables, such as mean (or median) time to HIV progression for each treatment group, or time at which a certain proportion of patients experienced HIV progression for each treatment group.

Second, the viral load data could . . . [Full Text of this Article]



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

RELATED ARTICLE

Evaluation of HIV-1 Immunogen, an Immunologic Modifier, Administered to Patients Infected With HIV Having 300 to 549 x 106/L CD4 Cell Counts: A Randomized Controlled Trial
James O. Kahn, Deborah Weng Cherng, Kenneth Mayer, Henry Murray, Stephen Lagakos, and for the 806 Investigator Team
JAMA. 2000;284(17):2193-2202.
ABSTRACT | FULL TEXT  






HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2001 American Medical Association. All Rights Reserved.